vTv Therapeutics Announces Phase 2b Azeliragon Data Selected for Oral Presentation at the 2016 Alzheimer’s Association International Conference Azeliragon MOA designed to inhibit RAGE, which affects Aβ accumulation, tau hyperphosphorylation and chronic inflammation – three of the principal causes of neuronal damage in AD vTv Therapeutics Inc. (Nasdaq:VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of new orally administered treatments for Alzheimer’s disease and diabetes, today announced that the Company will deliver an oral presentation on its lead product candidate azeliragon at the 2016 Alzheimer’s Association International Conference (AAIC). The...
↧